Pharmosa Biopharm (國邑)* announced that its partner, Liquidia Corporation, revealed at the 44th Annual J.P. Morgan Healthcare Conference the initiation of patient recruitment for Re-Spire, a global multi-center pivotal Phase III clinical trial for L606. This marks a significant milestone in the global expansion of L606 for the treatment of PH-ILD (Pulmonary Hypertension associated with Interstitial Lung Disease).

Market Opportunity & Technical Edge:

• Total Addressable Market (TAM): Liquidia announced plans to expand the prostacyclin inhalation therapy beyond PAH and PH-ILD (a $7B market) into indications such as COPD-associated PH, lung fibrosis, and scleroderma. The potential US market alone is estimated to exceed $18 billion.
• Liposomal Platform: General Manager Dr. Kan Pei highlighted that L606 utilizes proprietary liposome technology for sustained release, maintaining stable blood concentrations over 24 hours. This reduces dosing frequency, minimizes side effects, and improves patient compliance—a critical advantage for clinical enrollment.
• Trial Logistics: The Re-Spire trial targets approximately 350 subjects across more than 100 clinical sites in over 20 countries.
• Financial Impact: Gongwin* will recognize R&D milestone payments based on enrollment progress, providing significant near-term financial momentum.

Resource: 國邑＊全球首個長效霧化吸入藥物L606 啟動全球三期臨床